Rocket Pharmaceuticals, Inc. Payments to Acquire Investments
Rocket Pharmaceuticals, Inc. (RCKT) reported Payments to Acquire Investments of $63.53 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. payments to acquire investments for the quarter ending 2026-06-30 was $14.82M, a 71.87% decline year-over-year.
- Rocket Pharmaceuticals, Inc. payments to acquire investments for the quarter ending 2026-03-31 was $48.71M, a 65.19% decline year-over-year.
- Rocket Pharmaceuticals, Inc. payments to acquire investments for the quarter ending 2025-12-31 was $54.49M, a 56.07% decline year-over-year.
- Rocket Pharmaceuticals, Inc. payments to acquire investments for the quarter ending 2025-09-30 was $29.44M, a 52.37% increase year-over-year.
- Rocket Pharmaceuticals, Inc. payments to acquire investments for fiscal 2025 was $276.55M, a 12.47% increase from fiscal 2024.
- Rocket Pharmaceuticals, Inc. payments to acquire investments for fiscal 2024 was $245.89M, a 37.10% decline from fiscal 2023.
- Rocket Pharmaceuticals, Inc. payments to acquire investments for fiscal 2023 was $390.92M, a 3.88% increase from fiscal 2022.
- Rocket Pharmaceuticals, Inc. payments to acquire investments for fiscal 2022 was $376.33M, a 53.06% increase from fiscal 2021.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $63.53M 10-Q · filed 2026-08-10 | $118.03M derived: sum of 3 quarters · filed 2026-08-10 | $147.46M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $48.71M 10-Q · filed 2026-05-07 | $103.20M derived: sum of 2 quarters · filed 2026-05-07 | $132.64M derived: sum of 3 quarters · filed 2026-05-07 | $185.33M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $54.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $83.93M derived: sum of 2 quarters · filed 2026-02-26 | $136.62M derived: sum of 3 quarters · filed 2026-08-10 | $276.55M 10-K · filed 2026-02-26 |
| 2025-09-30 | $29.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $82.13M derived: sum of 2 quarters · filed 2026-08-10 | $222.06M 10-Q · filed 2025-11-06 | $346.10M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $52.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $192.62M 10-Q · filed 2026-08-10 | $316.67M derived: sum of 3 quarters · filed 2026-08-10 | $335.99M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $139.93M 10-Q · filed 2026-05-07 | $263.98M derived: sum of 2 quarters · filed 2026-05-07 | $283.30M derived: sum of 3 quarters · filed 2026-05-07 | $321.87M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $124.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $143.37M derived: sum of 2 quarters · filed 2026-02-26 | $181.94M derived: sum of 3 quarters · filed 2026-02-26 | $245.89M 10-K · filed 2026-02-26 |
| 2024-09-30 | $19.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $57.89M derived: sum of 2 quarters · filed 2025-11-06 | $121.84M 10-Q · filed 2025-11-06 | $330.34M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $38.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $102.52M 10-Q · filed 2025-08-07 | $311.02M derived: sum of 3 quarters · filed 2025-08-07 | $324.51M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $63.95M 10-Q · filed 2025-05-08 | $272.45M derived: sum of 2 quarters · filed 2025-05-08 | $285.94M derived: sum of 3 quarters · filed 2025-05-08 | $358.83M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $208.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $221.99M derived: sum of 2 quarters · filed 2025-02-27 | $294.89M derived: sum of 3 quarters · filed 2025-02-27 | $390.92M 10-K · filed 2025-02-27 |
| 2023-09-30 | $13.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $86.38M derived: sum of 2 quarters · filed 2024-11-07 | $182.42M 10-Q · filed 2024-11-07 | $381.29M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $72.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $168.93M 10-Q · filed 2024-08-06 | $367.80M derived: sum of 3 quarters · filed 2025-02-27 | $402.23M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $96.03M 10-Q · filed 2024-05-07 | $294.90M derived: sum of 2 quarters · filed 2025-02-27 | $329.34M derived: sum of 3 quarters · filed 2025-02-27 | $329.34M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $198.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $233.30M derived: sum of 2 quarters · filed 2025-02-27 | $233.30M derived: sum of 3 quarters · filed 2025-02-27 | $376.33M 10-K · filed 2025-02-27 |
| 2022-09-30 | $34.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $34.44M derived: sum of 2 quarters · filed 2023-11-07 | $177.46M 10-Q · filed 2023-11-07 | $196.85M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $143.02M 10-Q · filed 2023-08-09 | $162.41M derived: sum of 3 quarters · filed 2024-02-27 | $230.33M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $143.02M 10-Q · filed 2023-05-05 | $162.41M derived: sum of 2 quarters · filed 2024-02-27 | $230.33M derived: sum of 3 quarters · filed 2024-02-27 | $285.08M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $19.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $87.30M derived: sum of 2 quarters · filed 2024-02-27 | $142.06M derived: sum of 3 quarters · filed 2024-02-27 | $245.88M 10-K · filed 2024-02-27 |
| 2021-09-30 | $67.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $122.67M derived: sum of 2 quarters · filed 2022-11-04 | $226.48M 10-Q · filed 2022-11-04 | $303.73M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $54.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $158.57M 10-Q · filed 2022-08-09 | $235.81M derived: sum of 3 quarters · filed 2023-02-28 | $311.48M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $103.81M 10-Q · filed 2022-05-06 | $181.06M derived: sum of 2 quarters · filed 2023-02-28 | $256.72M derived: sum of 3 quarters · filed 2023-02-28 | $289.68M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $77.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $152.91M derived: sum of 2 quarters · filed 2023-02-28 | $185.86M derived: sum of 3 quarters · filed 2023-02-28 | $209.34M 10-K · filed 2023-02-28 |
| 2020-09-30 | $75.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $108.62M derived: sum of 2 quarters · filed 2021-11-05 | $132.10M 10-Q · filed 2021-11-05 | $166.15M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $32.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $56.44M 10-Q · filed 2021-08-09 | $90.49M derived: sum of 3 quarters · filed 2022-02-28 | $100.40M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $23.48M 10-Q · filed 2021-05-10 | $57.53M derived: sum of 2 quarters · filed 2022-02-28 | $67.44M derived: sum of 3 quarters · filed 2022-02-28 | $207.78M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $34.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $43.96M derived: sum of 2 quarters · filed 2022-02-28 | $184.30M derived: sum of 3 quarters · filed 2022-02-28 | $184.30M 10-K · filed 2022-02-28 |
| 2019-09-30 | $9.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $150.25M derived: sum of 2 quarters · filed 2020-11-06 | $150.25M 10-Q · filed 2020-11-06 | $150.25M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $140.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $140.34M 10-Q · filed 2020-08-05 | $140.34M derived: sum of 3 quarters · filed 2021-03-01 | $162.60M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-08 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $22.27M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $22.27M derived: sum of 2 quarters · filed 2021-03-01 | $141.09M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $22.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $141.09M 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | $118.82M 10-Q · filed 2019-08-08 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $0.00 derived: sum of 2 quarters · filed 2019-03-08 | $0.00 10-K · filed 2019-03-08 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $0.00 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-14 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |